GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.
Conference Call Details | |
Date: | Friday, March 27 |
Time: | 8:30 am Eastern Time |
Domestic: | 877-423-9813 |
International: | 201-689-8573 |
Conference ID: | 13701071 |
Webcast: | http://public.viavid.com/index.php?id=138792 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.
Contacts: | |
Will Brown | Ashley R. Robinson |
Chief Financial Officer | LifeSci Advisors, LLC |
Phone: 240-654-1450 | 617-430-7577 |
wbrown@altimmune.com | arr@lifesciadvisors.com |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.